> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Plans BLA for Migraine Prevention
- URL: https://www.fdaweb.com/lilly-plans-bla-for-migraine-prevention/
- Published: 2017-06-12T12:00:00.000Z
- Updated: 2026-09-14T22:28:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138904

Eli Lilly says it is planning a BLA before year-end after reporting positive results from three Phase 3 studies of galcanezumab, an investigational treatment for preventing episodic and chronic migraine, including data on several key secondary endpoints for galcanezumab compared to placebo at both studied doses. Data from EVOLVE-1 and EVOLVE-2 showed that patients with episodic migraine treated with galcanezumab 120 mg and 240 mg doses experienced a statistically significant decrease in the average number of monthly migraine headache days compared to patients treated with placebo. Galcanezumab is a monoclonal antibody designed to bind to and inhibit the activity of calcitonin gene-related peptide, which is believed to play a role in migraine and cluster headache, according to Lilly.